Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2003;2002(1):CD002047.
doi: 10.1002/14651858.CD002047.

Leflunomide for treating rheumatoid arthritis

M Osiri  1 , B Shea, V Robinson, M Suarez-Almazor, V Strand, P Tugwell, G Wells
Affiliations
Meta-Analysis

Leflunomide for treating rheumatoid arthritis

M Osiri et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. Leflunomide, as an inhibitor of pyrimidine synthesis, has a different mechanism of action than other existing disease modifying anti-rheumatic drugs (DMARD).

Objectives: To determine the efficacy and toxicity of leflunomide compared to placebo or other DMARDs in the treatment of RA.

Search strategy: We conducted a search in MEDLINE, EMBASE, Current Contents and the Cochrane Controlled Trial Register for trials up to December 2001. We also hand-searched reference lists and consulted content experts.

Selection criteria: Two independent reviewers selected the trials that met predetermined inclusion criteria.

Data collection and analysis: Two independent reviewers extracted data and assessed methodologic quality using standardized forms.

Main results: Six trials were included in this review. Using the ACR20 improvement criteria, there was an absolute difference in improvement of 28% (95% confidence interval: 21 - 35%) favouring leflunomide (232 out of 413 leflunomide treated patients compared to 89 out of 311 placebo patients met the criteria). There was no difference in ACR20 response rate between the patients treated with leflunomide and SSZ or MTX at 6 and 12 months. Other clinical outcomes were improved significantly in the leflunomide group compared to placebo but not different from SSZ or MTX. Withdrawals due to adverse events with leflunomide were 10% greater than placebo (70 out of 416 compared to 18 out of 311 respectively). Important adverse events included gastrointestinal symptoms, elevated liver function tests, alopecia, and infections. Overall adverse events and withdrawals in the leflunomide group were not significantly different from SSZ or MTX.

Reviewer's conclusions: Leflunomide appears to improve all clinical outcomes and delay radiologic progression at both 6 and 12 months of treatment compared to placebo. Its efficacy and adverse events at 2 years of treatment are comparable to SSZ and MTX. Long-term efficacy and toxicity remains to be established.

PubMed Disclaimer

Conflict of interest statement

None

References

References to studies included in this review

Amit 2004 {published data only}
    1. Amit M. A comparative 2‐year clinical study of combined leflunomide and methotrexate vs methotrexate alone as DMARD in rheumatoid arthritis. Abstract book, the 11th APLAR meeting, Jeju, South Korea. Seoul, Sep 2004:93.
Amit 2006 {published data only}
    1. Amit M, Rakhee M. A comparative 3‐year clinical study of combined leflunomide and methotrexate vs methotrexate alone as DMARD in rheumatoid arthritis. The Journal of Rheumatology 2006;9 Suppl 1:A190.
Antony 2006 {published data only}
    1. Antony T, Jose VM, Paul BJ, Thomas T. Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Indian Journal of Medical Sciences 2006;60(8):318‐26. - PubMed
Bao 2000 {published data only}
    1. Bao CD, Huang WQ, Chen SL, Gu YY. Treatment of rheumatoid arthritis with leflunomide: a double blind, randomised controlled study. China Journal of Rheumatology 2000;4:44‐6.
Bao 2003 {published data only}
    1. Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, et al. Leflunomide, a new disease‐modifying drug for treating active rheumatoid arthritis in methotrexate‐controlled phase II clinical trial. Chinese Medical Journal 2003;116(8):1228‐34. - PubMed
Cohen 2001 {published data only}
    1. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. for the Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group, Strand V. Two‐year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis and Rheumatism 2001;44(9):1984‐92. - PubMed
Dougados 2005 {published data only}
    1. Dougados M, Emery P, Lemmel EM, Zerbini CAF, Brin S, Riel P. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?. Annals of the Rheumatic Diseases 2005;64(5):44‐51. - PMC - PubMed
Emery 1999 {published and unpublished data}
    1. Emery P, Breedveld FC, Jubb RW, Sorensen H, Oed C, Loew‐Friedrich I. Efficacy and safety of leflunomide vs. methotrexate in rheumatoid arthritis (RA): results of a double‐blind, randomized, 2‐year trial. Arthritis and Rheumatism 1999;42 Suppl(9):271.
    1. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39(6):655‐65. - PubMed
    1. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Data on file, Hoechst Marion Roussel (Bridgewater) Nov 2, 1999.
    1. United States Food, Drug Administration. Summary basis of approval, leflunomide: NDA 20‐905. Summary basis of approval, United States Department of Health and Human Services. Vol. ND 20‐905, 1997:2‐22.
Fiehn 2007 {published data only}
    1. Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmuller G, Richter C, et al. Eight versus 16‐week re‐evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. Rheumatology International 2007;27(10):975‐9. - PubMed
Gao 2004 {published data only}
    1. Gao JS, Wu H, Chen YJ, Li F, Tian J, Xie X. Observation on the short‐term curative effect and safety on combination use of LEF plus MTX in the treatment of active and severe RA. Abstract book, the 11th APLAR meeting, Jeju, South Korea. Seoul, Sep 2004:92.
Hu 2001 {published data only}
    1. Hu Y, Tu S, Liu P. A randomized, controlled, single‐blind trial of leflunomide in the treatment of rheumatoid arthritis. Journal of Tongji Medical University 2001;21(1):72‐4. - PubMed
Jakez‐Ocampo 2002 {published data only}
    1. Jakez‐Ocampo J, Richaud‐Patin Y, Simón A, Llorente L. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint, Bone, Spine: Revue du Rhumatisme 2002;69:307‐11. - PubMed
Jiang 2001 {published data only}
    1. Jiang LD, Yu Q, Mei ZW. Efficacy in Active Rheumatoid Arthritis Treated by Leflunomide in Comparison with Methotrexate: A Randomized and Controlled Trial. Clinical Medical Journal of China 2001;8(2):157‐8.
Kalden 2001 {published data only}
    1. Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, et al. for the Eurpoean Leflunomide Study Group. Improved functional ability in patients with rheumatoid arthritis ‐ long term treatment with leflunomide versus sulfasalazine. The Journal of Rheumatology 2001;28(9):1983‐91. - PubMed
Karanikolas 2006 {published data only}
    1. Karanikolas G, Charalambopoulos D, Andrianakos A, Antoniades C, Katsilambros N. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. The Journal of Rheumatology 2006;33(3):486‐9. - PubMed
Kremer 2002 {published data only}
    1. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine 2002 Nov 5;137(9):726‐33. - PubMed
Kremer 2004 {published data only}
    1. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, et al. Combination leflunomide and methotrexate therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open‐label extension of a randomized, double‐blind, placebo controlled trial. The Journal of Rheumatology 2004;31(8):1521‐31. - PubMed
Lao 2001 {published data only}
    1. Lao ZY, Ni LQ, Zhang ZF, Zhou JL, et al. Leflunomide in treating rheumatoid arthritis: a double‐blind study. Chinese Journal of New Drugs and Clinical Remedies 2001;20(2):94‐7.
Lao 2002 {published data only}
    1. Lao ZY, Chen JH. Leflunomide combined with MTX in the treatment of rheumatoid arthritis. Abstract book, the 10th APLAR congress, Bangkok, Thailand. Bangkok, Dec 2002:140.
Larsen 2001 {published data only}
    1. Larsen A, Kvien T, Schattenkirchner M, Rau R, Scott DL, Smolen JS, et al. European Leflunomide Study Group. Slowing of disease progression in rheumatoid arthritis patients during long‐term treatment with leflunomide or sulfasalazine. Scandinavian Journal of Rheumatology 2001;30(3):135‐42. - PubMed
Lau 2002 {published data only}
    1. Lau CS, on behalf of the ARAVA Asia Study Group. Leflunomide (LEF) versus low dose methotrexate (MTX) in adult Asian patients with active rheumatoid arthritis (RA). Abstract book, the 10th APLAR congress, Bangkok, Thailand. Bangkok, Dec 2002:141.
Mariette 2004 {published data only}
    1. Mariette X, Bijlsma JWJ, Herold M, Eiselstein J, Spencer‐Green GT, Kupper H. Efficacy evaluation of adalimumab (Humira®) in combination with single and multiple disease modifying antirheumatic drugs in the REACT trial. Annals of the Rheumatic Diseases 2004;63 Suppl 1:278.
Mladenovic 1995 {published data only}
    1. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis and Rheumatism 1995;38(11):1595‐603. - PubMed
Poor 2004 {published data only}
    1. Poor G for the Leflunomide Multinational Study Group, Strand V. Efficacy and safety of leflunomide 10 mg vs 20 mg once daily in patients with active rheumatoid arthritis: multinational double‐blind, randomized trial. Rheumatology (Oxford) 2004;43(6):744‐9. - PubMed
Reece 2002 {published data only}
    1. Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis and Rheumatism 2002;46(2):366‐72. - PubMed
Rozman 1994a {published data only}
    1. Rozman B, Domijan Z, Popovic M, Mladenovic V, Mihajlovic D, Jajic I, Zivkovic M, Leflunomide Study Group, Croatia, Slovenia, Yugoslavia. Low‐Friedrich I, Oed Ch, Seifert H, Strand V. Weekly administration of leflunomide to patients with active rheumatoid arthritis. Arthritis and Rheumatism 1994;37 Suppl 9:339. - PubMed
Scott 2001 {published data only}
    1. Scott DL, Smolen JS, Kalden JR, Putte LBA, Larsen A, Kvien TK, et al for the European Leflunomide Study Group. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Annals of the Rheumatic Diseases 2001;60(10):913‐23. - PMC - PubMed
Sharp 2000 {published data only}
    1. Sharp JT, Strand V, Leung H, Hurley F, Loew‐Friedrich I, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis and Rheumatism 2000;43(3):495‐505. - PubMed
Shuai 2002 {published data only}
    1. Shuai ZW, Liu S, Shun GH, Xue JH, Xue SY. The phase II clinical trial of leflunomide in treatment of rheumatoid arthritis. Acta Universitatis Medicinalis Anhui 2002;37(1):41‐4.
Smolen 1999 {published data only}
    1. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double‐blind, randomised, multicentre trial. Lancet 1999;353:259‐66. - PubMed
Strand 1999a {published and unpublished data}
    1. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Archives in Internal Medicine 1999;159:2542‐50. - PubMed
Strand 1999b {published data only}
    1. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health‐related quality of life: results form a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis and Rheumatism 1999;42(9):1870‐8. - PubMed
Wislowska 2007 {published data only}
    1. Wislowska M, Jakubicz D. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF‐α blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatology International 2007;27:641‐7. - PubMed

References to studies excluded from this review

Balabanova 2004 {published data only}
    1. Balabanova RM, Makolkin VI, Shostak NA, Chichasova NV, Olyunin YuA, Goryachev DV, et al. Changes in indices of inflammatory activity in patients with rheumatoid arthritis during early stages of basic therapy with leflunomide. Terapevticheskii Arkhiv 2004;76(5):28‐32. - PubMed
Balabanova 2006 {published data only}
    1. Balabanova RM, Kashevarov RIu, Oliunin IuA, Smirnov AV, Aleksandrova EN. An antidestructive effect of leflunomide in early rheumatoid arthritis. Terapevticheskii Arkhiv 2006;78(6):6‐10. - PubMed
Dougados 2003 {published data only}
    1. Dougados M, Emery P, Lemmel EM, Serna R, Zerbini CA, Brin S, Riel P. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6‐month data. The Journal of Rheumatology 2003;30(12):2572‐9. - PubMed
Godinho 2004 {published data only}
    1. Godinho F, Godfrin B, Mahou S, Navaux F, Zabraniecki L, Cantagrel A. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clinical and Experimental Rheumatology 2004;22(3):328‐30. - PubMed
Grijalva 2007 {published data only}
    1. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR. Assessment of adherence to and persistence on disease‐ modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Medical Care 2007;45 Suppl 2(10):66‐76. - PubMed
Hansen 2004 {published data only}
    1. Hansen KE, Cush J, SInghal A, Cooley DA, Cohen S, Patel SR, et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis and Rheumatism 2004;51(2):228‐32. - PubMed
Jevtic 1997 {published data only}
    1. Jevtic V, Watt I, Rozman B, Kos‐Golja M, Praprotnik S, Logar D, et al. Contrast enhanced Gd‐DTPA magnetic resonance imaging in the evaluation of rheumatoid arthritis during a clinical trial with DMARDs. A prospective two‐year follow‐up study on hand joints in 31 patients. Clinical and Experimental Rheumatology 1997;15:151‐6. - PubMed
Ju 2007 {published data only}
    1. Ju JH, Kim SI, Lee JH, Lee SI, Yoo WH, Choe JY, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis and Rheumatism 2007 Jun;56(6):2094‐6. - PubMed
Kalden 2003 {published data only}
    1. Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five‐year followup study. Arthritis and Rheumatism 2003;48(6):1513‐20. - PubMed
Kraan 2004 {published data only}
    1. Kraan MC, Smeets TJ, Loon MJ, Breedveld FC, Dijkmans BA, Tak PP. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Annals of the Rheumatic Diseases 2004;63(9):1056‐61. - PMC - PubMed
Kuzmanova 2003 {published data only}
    1. Kuzmanova SI, Solakov PT, Batalov AZ, Staikova ND, Andreev SA, Russafov PB. Leflunomide in the treatment of refractory rheumatoid arthritis. Folia Medica (Plovdiv) 2003;45(3):43‐7. - PubMed
Litinsky 2006 {published data only}
    1. Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I, et al. The effect of leflunomide on clinical parameters and serum levels of IL‐6, IL‐10, MMP‐1, and MMP‐3 in patients with resistant rheumatoid arthritis. Cytokine 2006;33(2):106‐10. - PubMed
Mroczkowski 1999 {published data only}
    1. Mroczkowski PJ, Weinblatt ME, Kremer JM. Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis. Clinical and Experimental Rheumatology 1999;17 Suppl 18(6):66‐8. - PubMed
Popovic 1998 {published data only}
    1. Popovic M, Stefanovic D, Pejnovic N, Popovic R, Glisic B, Obradovic S, et al. Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporin, and levamisole) in patients with rheumatoid arthritis. Transplantation Proceedings 1998;30(8):4135‐6. - PubMed
Richards 2007 {published data only}
    1. Richards BL, Spies J, McGill N, Richards GW, Vaile J, Bleasel JF, Youssef PP. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Internal Medicine Journal 2007;37(2):101‐7. - PubMed
Rozman 1994b {published data only}
    1. Rozman B, Domljan Z, Popovic M, Mladenovic D, Mihajlovic I, Jajic M, Zivkovic M, Leflunomide Study Group, Croatia, Slovenia, Yugoslavia. Low‐Friedrich I, Oed Ch, Seifert H, Strand V. Long term administration of leflunomide to patients with rheumatoid arthritis (RA). Arthritis and Rheumatism 1994;37 Suppl(9):339. - PubMed
Sarunhan‐Direskeneli 2007 {published data only}
    1. Saruhan‐Direskeneli G, Inanc M, Fresko I, Akkoc N, Dalkilic E, Erken E, et al. The role of HLA‐DRB1 shared epitope alleles in predicting short‐term response to leflunomide in rheumatoid arthritis. Rheumatology 2007;46(12):1842‐4. - PubMed
Strand 2005 {published data only}
    1. Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, et al. Leflunomide Rheumatoid Arthritis Investigators Groups. Physical function and health related quality of life: analysis of 2‐year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. The Journal of Rheumatology 2005;32(4):590‐601. - PubMed
Tchetverikov 2008 {published data only}
    1. Tchetverikov I, Kraan MC, El B, Hanemaaijer R, DeGroot J, Huizinga TW. Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients. Annals of the Rheumatic Diseases 2008;67(1):128‐30. - PubMed
van der Heijde 2004 {published data only}
    1. Heijde D, Kalden J, Scott D, Smolen J, Strand V. Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Annals of the Rheumatic Diseases 2004 Jun;63(6):737‐9. - PMC - PubMed
van der Kooij 2007 {published data only}
    1. Kooij SM, Vries‐Bouwstra JK, Goekoop‐Ruiterman YP, Zeben D, Kerstens PJ, Gerards AH, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Annals of the Rheumatic Diseases 2007;66(10):1356‐62. - PMC - PubMed
van Riel 2003 {published data only}
    1. Riel P. Lelfunomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate. Clinical and Experimental Rheumatology 2003;21(6):695‐6. - PubMed
van Roon 2005 {published data only}
    1. Roon EN, Jansen TL, Laar MA, Janssen M, Yska JP, Keuper R, et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2005 Apr;64(4):569‐74. - PMC - PubMed
Weinblatt 1999b {published data only}
    1. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis and Rheumatism 1999;42(7):1322‐8. - PubMed

References to studies awaiting assessment

Raczkiewicz‐Papierska2007 {published data only}
    1. Raczkiewicz‐Papierska A, Dudek A, Bachta A, Thustochowicz M, Zawadyl B, Sulek M. Leflunomide as a second choice treatment in patients with rheumatoid arthritis. Polski Merkuriusz Lekarski 2007;22(132):547‐50. - PubMed
Shevchuk 2003 {published data only}
    1. Shevchuk SV, Stanislavchuk MA, Pentiuk OO. Efficacy and safety of treatment with methotrexate, leflunomide, detralex, and their combination of patients with rheumatoid arthritis. Likarska Sprava 2003, (3‐4):34‐41. - PubMed
Zhang 2004 {published data only}
    1. Zhang X, Cui Y, Luo Q, Yao RY, Zhou H. Methotrexate combined with leflunomide or hydroxychloroquine in the treatment of rheumatoid arthritis. Zhonghua Yi Xue Za Zhi 2004;84(12):1038‐40. - PubMed
Zhao 2006 {published data only}
    1. Zhao YX, Liu Y. Clinical observation on effects of leflunomide and total glucosides of paeony on rheumatoid arthritis. Chinese Journal of Integrated Traditional and Western Medicine 2006;26(4):355‐7. - PubMed

Additional references

Alarcon 1995
    1. Alarcon GS. Epidemiology of rheumatoid arthritis. Rheumatic Diseases Clinics of North America 1995;21:589‐604. - PubMed
Arnett 1988
    1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31:315‐24. - PubMed
Egsmose 1995
    1. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early second line therapy: 5‐year follow up of a prospective, double blind, placebo controlled study. The Journal of Rheumatology 1995;22:2208‐13. - PubMed
Felson 1993
    1. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis. Arthritis and Rheumatism 1993;36:729‐40. - PubMed
Felson 1995
    1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis & Rheumatism 1995;38:727‐35. - PubMed
Fox 1998
    1. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. The Journal of Rheumatology 1998;25 Suppl(53):20‐6. - PubMed
Fries 1996
    1. Fries JF, Williams CA, Morfield D, Singh G, Sibley J. Reduction in long‐term disability in patients with rheumatoid arthritis by disease‐modifying antirheumatic drug‐based treatment strategies. Arthritis and Rheumatism 1996;39:616‐22. - PubMed
Furst 1999
    1. Furst DE. Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology 1999;38 Suppl 2:14‐8. - PubMed
Haynes 1994
    1. Haynes R, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. Journal of the American Medical Informatics Association 1994;1:447‐58. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Jadad 1996
    1. Jadad A, Moore A, Carrol D. Assessing the quality of randomized trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed
Maetzel 2002
    1. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5‐year strategy of conventional disease‐modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis and Rheumatism 2002;47(6):655‐61. - PubMed
Pincus 1999
    1. Pincus T, Stein CM. ACR20: clinical or statistical significance?. Arthritis and Rheumatism 1999;42(8):1572‐6. - PubMed
Rozman 1998
    1. Rozman B for the Leflunomide Investigators Group. Clinical experience with leflunomide in rheumatoid arthritis. The Journal of Rheumatology 1998;25 Suppl(53):27‐32. - PubMed
Saag 2008
    1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and Rheumatism 2008;59(6):762‐84. - PubMed
Schünemann 2008
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, and Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane handbook for systematic reviews of interventions. Version 5.0.1. The Cochrane Collaboration, Updated Sep 2008.
Simon 2000
    1. Simon LS, Yocum D. New and future drug therapies for rheumatoid arthritis. Rheumatology (Oxford) 2000;39 Suppl 1:36‐42. - PubMed
Smolen 2000
    1. Smolen JS, Emery P. Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology (Oxford) 2000;39 Suppl 1:48‐56. - PubMed
Tugwell 2004
    1. Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, Wells G (editors). Evidence‐based Rheumatology. London: BMJ Books, 2004.
van der Heijde 1993
    1. Heijde DM, Hof M, Riel PL, Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. The Journal of Rheumatology 1993;20:573‐81. - PubMed
van Gestel 1996
    1. Gestel AM, Prevoo ML, Hof MA, Rijswijk MH, Putte LB, Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis and Rheumatism 1996;39:34‐40. - PubMed
Verhagen 1998
    1. Verhagen AP, Vet HCW, Bie RA, Kessels AGH, Boers M, Bouter LM, Knipschild PG. The Delphi list: a criteria list for quality assessment of randomized controlled trials for conducting systematic review developed by Delphi consensus. Journal of Clinical Epidemiology 1998;51(12):1235‐41. - PubMed
Weinblatt 1999a
    1. Weinblatt ME. The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology 1999;38 Suppl 2:19‐23. - PubMed
Wolfe 1991
    1. Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. The Journal of Rheumatology 1991;18:1290‐7. - PubMed

References to other published versions of this review

Osiri 2003a
    1. Osiri M, Shea B, Robinson V, Suarez‐Almazor M, Strand V, Tugwell P, Wells G. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. The Journal of Rheumatology 2003;30(6):1182‐90. - PubMed
Osiri 2003b
    1. Osiri M, Shea B, Welch V, Suarez‐Almazor ME, Strand V, Tugwell P, Wells GA. Leflunomide for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD002047] - DOI - PMC - PubMed

MeSH terms